Alarming Tuberculosis Rate Among People Who Inject Drugs in Vietnam.
drug users
epidemiology
prevalence
risk factors
tuberculosis
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
12
07
2021
accepted:
03
11
2021
entrez:
2
2
2022
pubmed:
3
2
2022
medline:
3
2
2022
Statut:
epublish
Résumé
The tuberculosis (TB) epidemic is not homogeneous in the general population but presents high-risk groups. People who inject drugs (PWID) are such a group. However, TB among PWID remains largely undocumented. Our goal was to assess the prevalence of TB and the risk factors associated with TB among PWID in Vietnam. We implemented a cross-sectional survey among 2 community-based cohorts of human immunodeficiency virus (HIV)-positive and HIV-negative PWID in Hai Phong. Participants were screened for TB using questions on TB symptoms. Those who reported any symptom were accompanied by peers to the TB clinic for chest x-ray. If the latter was abnormal, a sputum was collected to perform an Xpert MTB/RIF test. A total of 885 PWID were screened for TB. For both cohorts, most PWID were male (>90.0%), with a median age of 42 years. Beside heroin injection, 52.5% of participants reported smoking methamphetamine, and 63.2% were on methadone. Among HIV-positive PWID (N = 451), 90.4% were on antiretroviral therapy and 81.6% had a viral load <1000 copies/mL. Using a complete-case analysis, the estimated TB prevalence was 2.3% (95% confidence interval [CI], 1.0-4.5) and 2.1% (95% CI, 0.8-4.2) among HIV-positive and HIV-negative people, respectively. Living as a couple, arrest over the past 6 months, homelessness, and smoking methamphetamine were independently associated with TB but not HIV infection. In the context of very large antiretroviral therapy coverage, this extremely high rate of TB among PWID requires urgent actions.
Sections du résumé
BACKGROUND
BACKGROUND
The tuberculosis (TB) epidemic is not homogeneous in the general population but presents high-risk groups. People who inject drugs (PWID) are such a group. However, TB among PWID remains largely undocumented. Our goal was to assess the prevalence of TB and the risk factors associated with TB among PWID in Vietnam.
METHODS
METHODS
We implemented a cross-sectional survey among 2 community-based cohorts of human immunodeficiency virus (HIV)-positive and HIV-negative PWID in Hai Phong. Participants were screened for TB using questions on TB symptoms. Those who reported any symptom were accompanied by peers to the TB clinic for chest x-ray. If the latter was abnormal, a sputum was collected to perform an Xpert MTB/RIF test.
RESULTS
RESULTS
A total of 885 PWID were screened for TB. For both cohorts, most PWID were male (>90.0%), with a median age of 42 years. Beside heroin injection, 52.5% of participants reported smoking methamphetamine, and 63.2% were on methadone. Among HIV-positive PWID (N = 451), 90.4% were on antiretroviral therapy and 81.6% had a viral load <1000 copies/mL. Using a complete-case analysis, the estimated TB prevalence was 2.3% (95% confidence interval [CI], 1.0-4.5) and 2.1% (95% CI, 0.8-4.2) among HIV-positive and HIV-negative people, respectively. Living as a couple, arrest over the past 6 months, homelessness, and smoking methamphetamine were independently associated with TB but not HIV infection.
CONCLUSIONS
CONCLUSIONS
In the context of very large antiretroviral therapy coverage, this extremely high rate of TB among PWID requires urgent actions.
Identifiants
pubmed: 35106311
doi: 10.1093/ofid/ofab548
pii: ofab548
pmc: PMC8801226
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab548Subventions
Organisme : NIDA NIH HHS
ID : R01 DA041978
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Int J Tuberc Lung Dis. 2014 Jul;18(7):793-8
pubmed: 24902554
Sci Rep. 2019 Oct 18;9(1):15000
pubmed: 31628424
Clin Infect Dis. 1995 Nov;21(5):1253-64
pubmed: 8589151
JAMA. 2000 Jun 14;283(22):2968-74
pubmed: 10865275
AIDS. 2020 Dec 1;34(15):2305-2311
pubmed: 33048884
PLoS Pathog. 2009 Feb;5(2):e1000289
pubmed: 19197369
Drug Alcohol Depend. 2018 Apr 01;185:106-111
pubmed: 29432973
Lancet Infect Dis. 2019 Mar;19(3):e65-e76
pubmed: 30554995
Biochem Pharmacol. 2003 Jun 1;65(11):1761-6
pubmed: 12781327
Lancet Infect Dis. 2010 Jul;10(7):489-98
pubmed: 20610331
PLoS One. 2010 Dec 07;5(12):e15269
pubmed: 21151866
J Food Drug Anal. 2013 Dec;21(4):S42-S45
pubmed: 25278736
Int J Epidemiol. 2005 Aug;34(4):914-23
pubmed: 15914505
Lancet Infect Dis. 2017 May;17(5):e128-e143
pubmed: 28291721
BMJ. 2006 Jan 14;332(7533):85-7
pubmed: 16339219
Int J Tuberc Lung Dis. 2011 Jul;15(7):933-7
pubmed: 21682967
Eur Respir J. 2013 Jan;41(1):140-56
pubmed: 22936710
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
Cell Prolif. 2018 Oct;51(5):e12476
pubmed: 29956395
Clin Infect Dis. 2009 Jan 1;48(1):72-82
pubmed: 19046064
Int J Epidemiol. 2004 Feb;33(1):163-72
pubmed: 15075165
Thorax. 2007 Aug;62(8):667-71
pubmed: 17289861
J Infect Dis. 2017 Nov 3;216(suppl_6):S644-S653
pubmed: 29112745
Am J Public Health. 2010 Dec;100(12):2481-6
pubmed: 20167896
Int J Tuberc Lung Dis. 2013 Nov;17(11):1414-9
pubmed: 24125444
Int J Tuberc Lung Dis. 2002 Oct;6(10):887-94
pubmed: 12365575
Eur Respir J. 2017 Jul 13;50(1):
pubmed: 28705945
Int J Drug Policy. 2016 Apr;30:116-23
pubmed: 26964902
AIDS. 2017 Nov 13;31(17):2403-2413
pubmed: 28857827
Sci Rep. 2020 Apr 24;10(1):6999
pubmed: 32332986
Public Health Rep. 1994 May-Jun;109(3):319-27
pubmed: 8190855
Int J Tuberc Lung Dis. 2017 Aug 1;21(8):880-886
pubmed: 28786796
J Int AIDS Soc. 2015 Feb 16;18:19317
pubmed: 25690530
J Acquir Immune Defic Syndr. 2018 Jan 01;77(1):93-101
pubmed: 29016524
PLoS One. 2021 Apr 29;16(4):e0250038
pubmed: 33914753
Drug Alcohol Depend. 2018 May 1;186:219-225
pubmed: 29609134
PLoS Med. 2007 Jan;4(1):e20
pubmed: 17227135
Public Health Rep. 2014 Jan-Feb;129(1):78-85
pubmed: 24381363
Int J Tuberc Lung Dis. 2018 Feb 1;22(2):187-193
pubmed: 29506615
Int J Tuberc Lung Dis. 2017 Mar 1;21(3):327-332
pubmed: 28225344
J Infect Dis. 2017 Nov 3;216(suppl_6):S654-S661
pubmed: 29112743